Teva Pharmaceuticals Metoclopramide Recall: Foreign Tablets Prompt FDA Class II Action, Supply Chain Impact Looms
Teva Pharmaceuticals USA, Inc. has initiated a Class II nationwide recall for 36,612 cartons of Metoclopramide Tablets, USP 10 mg, due to the presence of foreign tablets/capsules. This event, stemming from manufacturing in Croatia, necessitates immediate review of procurement strategies and supply chain resilience for this critical generic medication across the United States.
FDA Mandates Class II Recall for Teva's Metoclopramide Tablets Due to Foreign Contamination
Teva Pharmaceuticals USA, Inc. has initiated a voluntary, firm-initiated Class II recall, identified as D-0473-2025, impacting 36,612 cartons of Metoclopramide Tablets, USP 10 mg. This significant regulatory action, initiated on May 23, 2025, and classified by the FDA on June 20, 2025, stems from a critical quality control failure: the confirmed presence of foreign tablets or capsules within the product packaging. The affected product, specifically lot number 5420094 with an expiration date of September 30, 2027, was distributed nationwide across the USA. For procurement directors, this recall signals an immediate need to quarantine existing stock of the affected lot and verify the integrity of all Metoclopramide inventory sourced from Teva. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This necessitates prompt action to mitigate patient risk and ensure compliance with FDA guidelines. Regulatory affairs heads must immediately assess the potential for broader scrutiny on their own product lines, particularly those with similar manufacturing profiles or supply chain complexities, as the FDA's focus on product integrity intensifies.
Manufacturing Origin and Supply Chain Vulnerability for Metoclopramide
The recalled Metoclopramide Tablets, USP 10 mg, bearing NDC 0093-2203-01, were manufactured in Croatia by Pliva Hrvatska, d.o.o., Zagreb, for Teva Pharmaceuticals, Parsippany, NJ 07054. This international manufacturing origin highlights a common, yet critical, point of vulnerability in global pharmaceutical supply chains. For supply chain VPs, this event underscores the imperative of robust oversight mechanisms for contract manufacturing organizations (CMOs) located outside domestic jurisdictions. The incident with Pliva Hrvatska, d.o.o. demonstrates that even established global manufacturers can experience significant quality deviations, leading to widespread recalls. The fact that Teva Pharmaceuticals USA, Inc. is the recalling firm, despite the product being manufactured by Pliva Hrvatska, means Teva bears the primary responsibility for the quality and safety of the drug marketed under its name in the U.S. This structure demands rigorous qualification and ongoing auditing of all third-party manufacturers, particularly those supplying essential generic medications like Metoclopramide, which is crucial for treating nausea and gastroparesis. Business development executives should evaluate their partnerships with foreign manufacturers, ensuring contractual agreements include stringent quality metrics and clear accountability for product integrity failures.
Assessing Supply Chain Exposure and Market Impact for Teva's Generic Metoclopramide
The recall of 36,612 cartons of Metoclopramide Tablets, USP 10 mg, distributed nationwide across the USA, directly impacts Teva Pharmaceuticals USA, Inc.'s market presence for this specific generic drug. As a major player in the generic pharmaceutical sector, Teva's recall of a widely used medication like Metoclopramide creates immediate supply chain disruptions for pharmacies, hospitals, and distributors relying on this product. Procurement directors must quantify their current inventory exposure and immediately identify alternative sources to prevent stock-outs. The Class II classification, while not indicating immediate life-threatening risk, still necessitates removal from the market, creating a gap that competitors may quickly fill. For business development executives, this presents both a challenge and a potential opportunity. While Teva faces a significant operational and reputational hurdle, other generic manufacturers of Metoclopramide may see increased demand. Understanding the market share dynamics for ANDA070184 and similar products is crucial for strategic positioning. Regulatory affairs teams should anticipate increased inquiries from customers and health authorities regarding their quality assurance processes, particularly concerning foreign-manufactured products.
Navigating Alternative Suppliers Amidst Generic Drug Recalls
The absence of readily available alternative supplier information in the public domain for Teva's Metoclopramide Tablets underscores a critical challenge for procurement teams. In situations like this Class II recall, where a significant quantity (36,612 cartons) of a widely distributed generic medication is affected, the immediate priority for procurement directors is to identify and qualify secondary or tertiary suppliers. While specific alternatives are not named in the available intelligence, the market for Metoclopramide Hydrochloride, a well-established generic, typically includes multiple manufacturers. However, the qualification process for new suppliers can be lengthy, involving extensive due diligence, facility audits, and regulatory approvals, potentially taking months. Supply chain VPs must proactively map their critical generic drug portfolios, identifying potential single points of failure and pre-qualifying diverse geographic sources to mitigate risks associated with manufacturing disruptions or quality issues from any single facility, such as Pliva Hrvatska, d.o.o. This incident serves as a stark reminder that reliance on a single source, even from a reputable global entity, can lead to significant operational and patient care challenges when quality failures occur.
Broader Regulatory Environment: Heightened Scrutiny on Pharmaceutical Quality
While the provided intelligence does not detail Teva Pharmaceuticals USA, Inc.'s specific regulatory history beyond this event, the recall of Metoclopramide Tablets occurs within a broader landscape of intensified FDA scrutiny on pharmaceutical quality and manufacturing compliance. Recent parallel events, such as Essential Wellness Pharma's Class II recall of Progesterone Injection due to sterility assurance failures in June 2026, and the FDA's hearing on Amgen's Tavneos market future, signal a consistent regulatory focus on product integrity and manufacturing standards. For regulatory affairs heads, this trend indicates that the FDA is actively monitoring and enforcing Good Manufacturing Practices (GMP) across the industry, irrespective of company size or product type. The presence of foreign tablets/capsules in Teva's product, manufactured by Pliva Hrvatska, d.o.o., highlights a fundamental breakdown in quality control that regulators are increasingly unwilling to tolerate. This environment necessitates that all pharmaceutical companies, particularly those relying on complex global supply chains, proactively review and fortify their quality management systems to preempt regulatory actions and safeguard market access.
Remediation Timeline and Strategic Implications for Supply Chain Continuity
The recall of Teva's Metoclopramide Tablets is currently classified as 'Ongoing,' indicating that the firm is actively working to remove the affected product from distribution channels and address the root cause of the foreign tablet contamination. For supply chain VPs, this 'ongoing' status means continued vigilance is required. Teva Pharmaceuticals USA, Inc. will be expected to conduct a thorough investigation into the manufacturing deviation at Pliva Hrvatska, d.o.o., implement corrective and preventive actions (CAPA), and provide comprehensive reports to the FDA. The FDA will monitor these actions closely, and depending on the severity and recurrence of the issue, may initiate further regulatory measures, including potential inspections of the manufacturing facility. Procurement directors must not only manage the immediate recall but also plan for potential long-term supply disruptions if the remediation process is protracted or if further regulatory actions impact Pliva Hrvatska's ability to supply the U.S. market. This event serves as a critical reminder for business development executives to diversify their product portfolios and reduce dependency on single-source generic drug formulations to ensure resilience against unforeseen quality incidents and regulatory interventions.